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faction. Both subscale scores and a composite score (CSS) can 
be calculated, with higher scores indicating greater satisfaction.
The OPSAT-Q, Osteoporosis Targeted Quality of Life (OptQoL),
three single-item global measures related to satisfaction, and
demographic questionnaires were self-administered to eligible
women recruited from four US clinics. Participants were diag-
nosed with osteoporosis or osteopenia and currently taking daily
or weekly bisphosphonate treatment. Reproducibility was
assessed via a follow-up questionnaire completed by participants
two-weeks post baseline. Analyses included item and scale per-
formance, internal consistency reliability, reproducibility, and
construct validity. RESULTS: A total of 104 women with a mean
age of 65 years participated. The majority was white (64.4%),
living with someone (74%), and not currently employed
(58.7%). On a scale of 0–100, individual patient subscale scores
ranged from 17 to 100 and CSS scores ranged from 44–100. All
scores showed acceptable internal consistency reliability (Cron-
bach’s a > 0.70) (range 0.72 to 0.89). Reproducibility exceeded
0.70 for all scores except Conﬁdence with Daily Activity (0.62)
and Overall Satisfaction (0.64). Signiﬁcant correlations were
found between the OPSAT-Q subscales and conceptually similar
global measures (p < 0.001). CONCLUSIONS: The ﬁndings
from this study provide evidence of the validity and reliability of
the OPSAT-Q and support the proposed composition of four
subscales and a composite score. They also support the use of
the OPSAT-Q to examine the impact of potentially more conve-
nient bisphosphonate dosing on patient satisfaction.
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OBJECTIVE: Is it safe to treat patients with opioids for chronic
non-malignant pain who have histories of substance abuse or
addicition? Mortality rates for substance abusers are three times
the general population rate. There are few outcome studies in
the medical literature. The Opioid Renewal Clinic follows
patients closely with drug testing, laboratory monitoring, and
provides group education with outside speakers. On site drug
counseling is provided to those determined to be in need. A 
full range of consultation services are available. The disciplines
that make up the clinc include Pharmacy, Nursing, Social 
Work, Internal and Addiction Medicine. Disease management
guidelines are incorporated into the structure of the clinic.
METHODS: This was a retrospective age adjusted mortality
study of 250 Primary Care consults over a two-year period to a
multidisciplinary Opioid Renewal Clinic. The most common
reason for consultation was the difﬁcult to manage patient sec-
ondary to substance abuse. The renewal clinic maintains between
80 to 100 patients. Kaplan-Meier survival curves were per-
formed for pain patients on opioids in Primary Care and the
opioid renewal clinic. Key variables were evaluated by regression
analysis. RESULTS: There were six deaths in patients in Primary
Care and two deaths in patients followed in the Renewal Clinic.
The odds ratio of deaths in usual care to clinic is three, or three
times the rate of the Renewal Clinic. Patients were between
40–60 years of age. Deaths due to known cancer, cardiac or liver
disease were excluded. Cancer deaths were predominantly lung,
and assosciated with tobacco use. CONCLUSIONS: A Multi-
disciplinary Opioid Renewal Clinic can reduce short term mor-
tatlity in high risk patients. Further studies are recommended 
to assess long term mortality rates and secondary outcomes 
on cancer prevention, disease management, and control of
depression.
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OBJECTIVES: Pain management centers provide the most
appropriate care for pure neuropathic pain. But before consult-
ing such a center, patients often indulge in “medical nomadism”,
thereby incurring substantial additional costs. This study aimed
to describe the medical trajectory and to estimate the direct costs
of a patient sample with pure neuropathic pain (i.e. with no noci-
ceptive component) during the year before their ﬁrst consulta-
tion in a pain management center. METHODS: Retrospective
data collected by patient questionnaires were used for this cross-
sectional study, in which ten pain management centers partici-
pated between January and April, 2004. A total of 116 patients
who gave written consent and were able to answer the ques-
tionnaire were assessed. The economic outcomes were the total
and refunded Direct Medical Consumption (DMC), including 
all costs directly related to the pathology: medical and para-
medical consultations, drugs, other treatments (surgery, nerve
stimulation, etc.), examinations, and hospitalizations. Costs
were determined by medical fees, ofﬁcial drugs and examinations
tariffs, and Diagnosis Related Groups (DRGs). A bootstrap 
technique was used to improve statistical strength. RESULTS:
The total and refunded average cost per patient ranges from
4650 € to 6830 € and from 3500 to 5690 €, depending on 
the hospitalization sector, private or public. The most costly
items are “Hospitalizations” and “other treatments”, represent-
ing 31% and 24% respectively of the total cost in the private 
sector, and 46% and 23% in the public sector. The “drugs” item
only represents 12% in the private and 8% in the public 
sector. CONCLUSION: This study, based mainly on recalled
declarative data, may be subjectively biased. Nonetheless, the
results give a plausible estimation of direct annual costs of 
neuropathic pain management in France before its appropriate
management in a specialized center, a ﬁeld where few data are
available.
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OBJECTIVES: To characterize hospital IV PCA pump and anal-
gesia acquisition, inventory, and logistics for acute postoperative
pain management. METHODS: Data were collected via inter-
views with 13 geographically diverse US hospitals during an
ongoing prospective, multi-center, observational study of IV PCA
for acute postoperative pain management among subjects under-
going total knee or hip replacement or abdominal hysterectomy.
An interim analysis was performed on data from 13 of 32
planned hospitals. RESULTS: Average IV PCA pump inventory
